secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001689375-24-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Q2 net income $55M, positive Phase 1 data for DMD candidate ENTR-601-44
-------------------------------------------------------------------------------

- Q2 net income of $55.0M vs net loss of $25.9M YoY; collaboration revenue $94.7M (up from $18.2M).
- Completed $100M registered direct offering; cash & securities $469.7M as of June 30, 2024; runway into 2027.
- Phase 1 trial of ENTR-601-44 showed dose-dependent plasma/muscle concentration and exon skipping; no serious adverse events.
- Planning global Phase 2 trials for ENTR-601-44 and ENTR-601-45; regulatory filings expected Q4 2024; ENTR-601-50 filing planned 2025.
- Vertex VX-670 DM1 trial enrolling; SAD portion expected to complete by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937524000045/0001689375-24-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937524000045/trda-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001689375-24-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer